Evidence map›Paper›PMID 35003088›Full record

ArticleFrontiers in immunology2021

An Integrated Platform for Serological Detection and Vaccination of COVID-19.

Sung-Chan Wei, Wei-Ting Hsu, Chun-Hsiang Chiu, Feng-Yee Chang, Huei-Ru Lo, Chuan-Yu Liao, Hwai-I Yang, Yu-Chi Chou, Chih-Hsuan Tsai, Yu-Chan Chao

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Sung-Chan WeiInstitute of Molecular Biology, Academia Sinica, Taipei, Taiwan.
Wei-Ting HsuInstitute of Molecular Biology, Academia Sinica, Taipei, Taiwan.
Chun-Hsiang ChiuDivision of Infectious Disease and Tropical Medicine, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
Feng-Yee ChangDivision of Infectious Disease and Tropical Medicine, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
Huei-Ru LoInstitute of Molecular Biology, Academia Sinica, Taipei, Taiwan.
Chuan-Yu LiaoInstitute of Molecular Biology, Academia Sinica, Taipei, Taiwan.
Hwai-I YangGenomics Research Center, Academia Sinica, Taipei, Taiwan.
Yu-Chi ChouBiomedical Translation Research Center, Academia Sinica, Taipei, Taiwan.
Chih-Hsuan TsaiInstitute of Molecular Biology, Academia Sinica, Taipei, Taiwan.
Yu-Chan ChaoInstitute of Molecular Biology, Academia Sinica, Taipei, Taiwan.
Institute of Molecular Biology, Academia Sinica · TWAcademia Sinica · TWGenomics Research Center, Academia Sinica · TWNational Chung Hsing University · TWNational Defense Medical Center · TWTri-Service General Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronavirus Disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), is an ongoing pandemic. Detection and vaccination are essential for disease control, but they are distinct and complex operations that require significant improvements. Here, we developed an integrated detection and vaccination system to greatly simplify these efforts. We constructed recombinant baculoviruses to separately display the nucleocapsid (N) and spike (S) proteins of SARS-CoV-2. Insect cells infected by the recombinant baculoviruses were used to generate a cell-based system to accurately detect patient serum. Notably, although well-recognized by our newly developed detection system in which S-displaying insect cells acted as antigen, anti-S antibodies from many patients were barely detectable by Western blot, evidencing that COVID-19 patients primarily produce conformation-dependent anti-S antibodies. Furthermore, the same baculovirus constructs can display N (N-Bac) or S (S-Bac) on the baculovirus envelope and serve as vector vaccines. Animal experiments show that S-Bac or N-Bac immunization in mice elicited a strong and specific antibody response, and S-Bac in particular stimulated effective neutralizing antibodies without the need for adjuvant. Our integrated system maintains antigen conformation and membrane structure to facilitate serum detection and antibody stimulation. Thus, compared with currently available technologies, our system represents a simplified and efficient platform for better SARS-CoV-2 detection and vaccination.

Indexed as

AdultAgedAged, 80 and overAnimalsAntibodies, NeutralizingAntibodies, ViralBaculoviridaeCell LineCell Surface Display TechniquesCoronavirus Nucleocapsid ProteinsCOVID-19COVID-19 VaccinesEnzyme-Linked Immunosorbent AssayFemaleHEK293 CellsHumansAntibodies, NeutralizingAntibodies, ViralCoronavirus Nucleocapsid ProteinsCOVID-19 Vaccinesnucleocapsid phosphoprotein, SARS-CoV-2PhosphoproteinsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2baculovirusCOVID-19SARS-CoV-2serological detectionvaccine

Identifiers

PMID35003088
PMCPMC8734241
OpenAlexW4206311483

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.